PLUSS2 Statistical Analysis Plan
收藏数据链接：
官方服务：
资源简介：
PLUSS 2 year outcomes Does administration of intratracheal budesonide during the early treatment of respiratory distress syndrome (RDS) in extremely preterm infants increase survival without moderate-severe neurodevelopmental disability at 2 years of age (corrected for prematurity), defined as any one or more of moderate or severe developmental delay, moderate or severe cerebral palsy, deafness, or blindness? Australian New Zealand Clinical Trials Registry; ACTRN12617000322336
创建时间：
2026-07-07
